HCWB NASDAQ
HCW Biologics Inc.
1W: -11.9%
1M: -49.4%
3M: -63.2%
YTD: -74.7%
1Y: -92.6%
3Y: -99.6%
5Y: -99.8%
$1.68
-0.01 (-0.59%)
Weekly Expected Move ±14.6%
$1
$1
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
24 relationships24
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2024-07-18
Earliest Filing
2026-03-17
Latest Filing
partner: 11
investor: 8
licensee: 4
JV: 1
Counterparties (Filed by HCWB)
24 relationshipsCompanies named in HCWB's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| CITIC Medical Fund | — | investor | Investor in licensee entity Trimmune | 2026-03-17 | View |
| TigerYeah Capital Fund of TigerMed | — | investor | Investor in licensee entity Trimmune | 2026-03-17 | View |
| Beijing Trimmune Biotech Co., Ltd. | — | licensee | Exclusive worldwide licensee for HCW11-006 molecule | 2026-03-17 | View |
| WY Biotech Co., Ltd. | — | partner | Co-founder of licensee entity Trimmune | 2026-03-17 | View |
| WY Biotech Co., Ltd. | — | partner | Partnered with HCW Biologics to form Trimmune and secure exclusive worldwide license for HCW11-006 | 2026-02-13 | View |
| Beijing Trimmune Biotech Co., Ltd. | — | JV | New joint venture entity formed by HCW Biologics and WY Biotech for development and commercialization of HCW11-006 | 2026-02-13 | View |
| CITIC Medical Fund | — | investor | Investor backing Trimmune providing financial support for the venture | 2026-02-13 | View |
| TigerMed | — | investor | Investor backing Trimmune via TigerYeah Capital Fund, providing initial funding | 2026-02-13 | View |
| Beijing Trimmune Biotech Co., Ltd. | — | partner | Entered into an Amended and Restated License, Research and Co-Development Agreement with HCW Biologics Inc. | 2025-11-19 | View |
| WY Biotech Co., Ltd. | — | partner | Assigned the original WY Biotech License to Beijing Trimmune Biotech Co., Ltd. | 2025-11-19 | View |
| WY Biotech Co., Ltd. | — | partner | Extension of payment deadline for upfront license fee under exclusive license agreement | 2025-09-05 | View |
| Square Gate Capital Master Fund, LLC - Series 4 | — | investor | Investor in an Equity Purchase Agreement for up to $20,000,000 worth of common stock. | 2025-08-15 | View |
| WY Biotech Co., Ltd. | — | licensee | Exclusive license agreement for upfront license fee payment | 2025-07-18 | View |
| WY Biotech Co., Ltd. | — | licensee | Exclusive worldwide license agreement for development and commercialization of HCW11-006 | 2025-06-04 | View |
| Square Gate Capital Master Fund, LLC - Series 4 | — | investor | Investor in Equity Purchase Agreement and holder of Commitment Shares | 2025-04-14 | View |
| Armistice Capital Master Fund Ltd. | — | investor | Holder of Common Stock Purchase Warrant for resale of up to 6,717,000 shares | 2025-04-14 | View |
| WY Biotech Co., Ltd. | — | partner | Amendment to License, Research and Co-Development Agreement regarding payment schedule and milestones due to CDMO delay | 2025-03-19 | View |
| Square Gate Capital Master Fund, LLC - Series 4 | — | investor | Investor in an equity purchase agreement to purchase up to $20,000,000 worth of HCW Biologics Inc. common stock. | 2025-02-21 | View |
| Maxim Group LLC | MMS | partner | Placement agent for the registered direct offering and private placement. | 2024-11-20 | View |
| WY Biotech | — | partner | Counterparty to a worldwide exclusive license agreement for developing and commercializing a preclinical immunotherapeut | 2024-11-20 | View |
| WY Biotech Co., Ltd. | — | licensee | Signed an exclusive worldwide License, Research, and Co-Development Agreement for a preclinical molecule. | 2024-11-18 | View |
| Altor BioScience, LLC | — | partner | Counterparty in settlement agreement resolving arbitration | 2024-07-18 | View |
| NantCell, Inc. | — | partner | Counterparty in settlement agreement resolving arbitration | 2024-07-18 | View |
| ImmunityBio, Inc. | IBRX | partner | Parent company of Altor and NantCell, counterparty in settlement agreement | 2024-07-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-24 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-09-10 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-08 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-08-14 | Financial Restatement | View | |
| 2026-08-14 | Earnings Release; Exhibits | View | |
| 2026-07-29 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-07-01 | Other Events | View | |
| 2026-06-30 | Delisting Notice; Exhibits | View | |
| 2026-06-26 | Bylaws Amendment; Regulation FD; Exhibits | View | |
| 2026-06-16 | Regulation FD; Exhibits | View | |
| 2026-06-15 | Shareholder Vote | View | |
| 2026-06-01 | Delisting Notice | View | |
| 2026-05-27 | Termination of Agreement; Exhibits | View | |
| 2026-05-21 | Material Agreement; Unregistered Equity Sales; Regulation FD; Other Events; Exhibits | Agreement | View |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-04-30 | Other Events; Exhibits | View | |
| 2026-04-30 | Other Events; Exhibits | View | |
| 2026-04-16 | Bylaws Amendment; Exhibits | View | |
| 2026-03-31 | Earnings Release; Exhibits | View | |
| 2026-03-17 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR